Cannabis Clinical Trials

Market News Tetra Bio-Pharma (TSXV:TBP; OTCQB:TBPMF) announced it received No Objection Letter (NOL) from the Therapeutic Products Directorate (TPD), Health Canada to evaluate the safety, pharmacokinetics and pharmacodynamics of its cannabis oil PPP005. As quoted in the press release: According to Health Canada data, the annual Canadian cannabis oil production for medical purposes was 22,766 kg […]

by

MyDx Engages Leading Israeli Hospital to Validate its Pain Management Formula MyDx’s Biopharmaceutical Division, which is focused on identifying green Active Pharmaceutical Ingredients (gAPITM), will conduct a randomized and placebo-controlled trial to estimate the efficacy of MyDx’s proprietary formulas on patients suffering from chronic Low Back Pain as a Primary indication.  The trial will also […]

by

In October, the Democratic members of the House Veterans Affairs Committee wrote a letter asking VA secretary David Shulkin why his department is not conducting research into medical marijuana. In the letter, ranking member Tim Walz (Minn.) and the other nine Democratic committee members note that in many states that have medical marijuana programs, cannabis […]

by

Market News Tetra Bio-Pharma (TSXV:TBP; OTCQB:TBPMF) announced it received No Objection Letter (NOL) from the Therapeutic Products Directorate (TPD), Health Canada to evaluate the safety, pharmacokinetics and pharmacodynamics of its cannabis oil PPP005. As quoted in the press release: According to Health Canada data, the annual Canadian cannabis oil production for medical purposes was 22,766 kg […]

by

RUATORIA-based Hikurangi Group has signed an agreement to work with Rhizo Sciences LLC, a cannabis industry development company based in Seattle, Washington. Hikurangi Group and Rhizo Sciences intend to establish the first pharmaceutical-grade GMP medical cannabis production and processing facility in New Zealand. This will allow Hikurangi Group to provide high-quality medical cannabis products to […]

by

The Food and Drug Administration (FDA), the Drug Enforcement Administration (DEA), and anti-cannabis activists like to claim that marijuana has no proven value as a medicine. Both the FDA and the DEA have resisted approval or funding for trials using actual marijuana. If marijuana has no medicinal value, why are there three FDA-approved pharmaceutical drugs […]

by

On 15 December 2017, the Danish Parliament adopted by unanimous vote a new Act on a pilot scheme on cannabis for medicinal use (the “Cannabis Act”). The scheme will be introduced on 1 January 2018. In anticipation of the final adoption of the Act, the Danish Medicines Agency (DMA) began in October 2017 to accept […]

by

Conditionally effective-patients with autism or sleep apnea can enroll July 1 and pick up medication Aug. 1. There are a statute-set limited number of outlets in this state. There are four in the Twin Cities and four in outstate Minnesota, which include St. Cloud, Rochester, Moorhead and Hibbing,” said Dr. Tom Arneson, research manager at […]

by

Vitality Biopharma has developed a cannabis-based potential treatment for inflammatory bowel diseases. Its annoucement about VITA-100 comes as U.S. regulators have been approving cannabis-based products for various disorders. VITA-100 delivers two of the active ingredients in cannabis plants to the intestinal tract to alleviate inflammation there. Those components are cannabidiol and tetrahydrocannabinol, or THC. Vitality calls the new class […]

by

CannaRoyalty to contribute Bodhi Research position into the JV in exchange for equity OTTAWA, Jan. 11, 2018 /CNW/ – CannaRoyalty Corp. (CSE: CRZ) (OTCQX: CNNRF) (“CannaRoyalty”) and Aequus Pharmaceuticals Inc. (TSX-V: AQS) (OTCQB: AQSZF) (“Aequus”) (together the “Partners”), today announced a collaboration (the “JV”) to advance a suite of cannabis-based therapies targeting neurological disorders into […]

by

By Glenn Ellis Depending on whom you talk to, medical marijuana (also known as cannabis) is either a panacea for everything from cancer, to chronic pain, to epilepsy or it’s a dangerous and illegal drug with no place in medicine. In 1996, California voters passed Proposition 215, making the Golden State the first in the […]

by